Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Mighell

Orthopaedic Surgery Temple Terrace, FL Medical Doctor

NPI 1528065323 CMS profile 23194

13020 N Telecom Pkwy, Temple Terrace, FL 33637

Open in the dashboard

General payments

$4,299,175

1,427 records reported · program years 2019–2025

Research payments

$31,896

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$81,938 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mark Mighell of Temple Terrace, FL is reported in the CMS Open Payments database as having received $4,299,175 across 1,427 general payments and $31,896 in research payments paid to them. Separately, studies naming them as principal investigator received $81,938 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $586,826 256
2024 General $623,932 252
2023 General $612,388 222
2023 Research $4,646 2
2022 General $576,433 170
2021 General $530,318 142
2020 General $666,117 114
2020 Research $1,000 1
2019 General $703,161 271
2019 Research $26,250 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mighell
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Mark Mighell were reported at $586,826. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Mark Mighell Orthopaedic Surgery median Middle half National median
2019 $703,161 $644 $140–$2,844 $163
2020 $666,117 $312 $75–$1,860 $114
2021 $530,318 $520 $117–$2,495 $132
2022 $576,433 $598 $128–$2,731 $149
2023 $612,388 $461 $128–$2,264 $160
2024 $623,932 $497 $134–$2,475 $164
2025 $586,826 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,764,091 1,139 payments
  2. Encore Medical, LP $464,801 95 payments
  3. Wright Medical Technology, Inc. $32,673 23 payments
  4. Medical Device Business Services, Inc. $14,829 8 payments
  5. Zimmer Biomet Holdings, Inc. $6,129 15 payments
  6. Pacira Pharmaceuticals Incorporated $5,694 6 payments
  7. MVP Orthopedics Inc $2,610 11 payments
  8. Coastal Medical Technologies LLC $1,570 20 payments
  9. Dunamis Medical, LLC $1,531 2 payments
  10. DePuy Synthes Sales Inc. $1,031 28 payments
  11. Other $4,217 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,955,225 53 payments
  2. Consulting Fee $1,170,289 314 payments
  3. Travel and Lodging $120,929 316 payments
  4. Food and Beverage $49,993 740 payments
  5. Education $2,740 4 payments
Products named General payments · program years 2019–2025
  1. REUNION Trauma & Extremeties $1,924,376 135 payments
  2. REUNION Trauma & Extremeties $1,054,484 198 payments
  3. TRUESIGHT $527,614 5 payments
  4. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $404,419 329 payments
  5. AEQUALIS PERFORM $268,185 102 payments
  6. TORNIER PERFORM REVERSED GLENOID $164,550 50 payments
  7. DJO Surgical Turon Modular Shoulder System $137,859 8 payments
  8. AEQUALIS PERFORM REVERSED $125,517 37 payments
  9. DJO SURGICAL $121,514 8 payments
  10. MAKO $118,821 96 payments
  11. Other $936,045 707 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Stryker Corporation $27,250 7 payments
  2. Dunamis Medical, LLC $4,646 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

447

Median for Orthopedic Surgery: 203

Drug cost

$2,285

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 94 $436
Meloxicam Generic 146 $377
Ibuprofen Generic 16 $326
Gabapentin Generic 25 $283
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $240
Methylprednisolone Generic 35 $224
Amoxicillin Generic 68 $184
Clindamycin Hcl Generic 24 $138
Tramadol Hcl Generic 16 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$376,538

Of which drugs: $15,665

Medicare patients

745

Average age 74

Services billed

8,176

411 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Depression 25%
Diabetes 24%
Chronic kidney disease 24%
Osteoporosis 21%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 355 2,748 $14,824
Injection, ketorolac tromethamine, per 15 mg J1885 Office 374 1,582 $833

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record